Element Solutions Inc. Common Stock vs NeoGenomics Inc. Common Stock — how do they compare? Element Solutions Inc. Common Stock trades at $35.59 (market cap $9.07B), while NeoGenomics Inc. Common Stock trades at $16.83 (market cap $2.14B). The key difference: Element Solutions Inc. Common Stock is far larger — about 4.2× NeoGenomics Inc. Common Stock's market cap, and Element Solutions Inc. Common Stock pays a 0.86% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Element Solutions Inc. Common Stock for 6 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| ESI | NEO | |
|---|---|---|
Market Cap | $9.07B | $2.14B |
Volume | 3,090,738 | 2,228,400 |
Sector | Basic Materials | Health |
52-Week High | $49.09 | $19.91 |
52-Week Low | $22.99 | $7.19 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.00B | $2.44B |
Dividend Yield | 0.86% | — |
Signals from Pluang's Aura AI — not financial advice
Element Solutions (ESI) trades at $37.20, up 2.06% today, with a neutral technical signal and bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats and robust revenue growth from $2.55B in 2025 to $3.2B projected for 2026. Recent developments include the termination of the Solstice merger and focus on AI-driven demand and operational efficiencies.
ESI presents a mixed outlook with strong fundamental growth offset by valuation concerns. The stock trades at a premium P/E of 50.27 with analyst consensus target of $47.90 suggesting 28.8% upside. Key risks include inflation pressures and uneven industrial demand, while catalysts include continued AI adoption and data center expansion driving future performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Element Solutions provides specialty chemical products and technical services. Its solutions support electronics, communications, automotive systems, industrial surface finishing, and offshore energy.
Read more on ESI →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →